Study first to show role of Parkin gene in eye lens free radical formation, cell survival
Although mutations in the PARK2 gene that encodes the Parkin protein are associated with developing early-onset Parkinson's disease (PD), much remains to be discovered about how Parkin functions in cells and how loss of Parkin function could contribute to PD and other degenerative diseases. Parkin is known to regulate the degradation of mitochondria that are cellular organelles that generate energy required for a multitude of cellular functions. Damage to mitochondria is associated with the production of free radicals during the aging process and is involved in the development of multiple diseases ranging from neurodegenerative diseases to cataract formation.
To discover new cellular functions for Parkin and how loss of Parkin function could contribute to age-related diseases, a team of researchers in the Charles E. Schmidt College of Medicine at Florida Atlantic University engineered eye lens cells to make either normal Parkin or a mutant form of Parkin, and examined whether Parkin function was required for lens cell mitochondrial function, and lens cell survival.
Results of the study, recently published in the journal Biochemica et Biophysica Acta: Molecular Basis of Disease, are the first to demonstrate that the Parkin gene is turned on when cells are exposed to environmental insults that cause free radical formation and cataract formation. They also discovered that through the removal of mitochondria that are damaged by these environmental insults, Parkin prevents free radical formation in lens cells and increases the ability of the cells to survive exposure to conditions that are associated with aging and the development of many degenerative diseases. The data suggest an important function for Parkin in promoting the survival of not only lens cells, but of many cells of the body including neurons, and they suggest that activation of the Parkin gene could prevent cell damage that is associated with age-related cataract formation and death of neurons associated with PD and other age-related degenerative diseases.
"We found that Parkin is necessary to maintain lens cell function and that loss of Parkin function likely contributes to the formation of cataracts and possibly other age-related degenerative diseases that are associated with loss of mitochondrial function and increased free radical formation," said Marc Kantorow, Ph.D., senior-author, professor of biomedical science, and assistant dean of graduate programs in FAU's Charles E. Schmidt College of Medicine. "Our findings suggest that Parkin plays a direct role in the prevention of oxidative stress through its ability to maintain cellular mitochondrial populations. Our data also suggests that the gene encoding Parkin is induced upon environmental damage so that drugs or genetic methods to increase Parkin levels and function could prove effective in the prevention of cataracts and other age-related degenerative diseases including neurological diseases like Parkinson disease."
Kantorow and co-authors Lisa Ann Brennan, Ph.D., research associate professor in FAU's College of Medicine, and Josef Khoury, a Master's degree student in the Kantorow Laboratory, hypothesized that Parkin also may be important for the embryonic development of the eye lens since regulation of mitochondrial function is a key feature of the development of all tissues.
"We found that levels of Parkin based on genomic sequencing of eye lens at different growth stages exhibited different levels of Parkin suggesting that Parkin had region-specific functions in the eye lens," said Brennan. "We were looking for genes that are changed during the normal growth and differentiation of lens cells to help identify those genes that control how undifferentiated stem-like cells become mature transparent eye lens cells."
It is estimated that more than 6 million people in the United States suffer from some kind of degenerative neurological condition including PD. Despite advances in surgical techniques, cataracts remain a significant cause of world blindness. It is estimated that any therapy that could delay the onset of cataracts by just 10 years, could reduce the number of cataract surgeries annually by half, and moreover, improve the quality of visual health care while reducing costs.
"The next step of our ongoing research is to work to establish how Parkin regulates the growth and development of the eye lens by controlling mitochondrial populations that are required for lens cell growth," said Kantorow. "We want to be able to identify the genetic mechanisms that regulate the production of Parkin in cells and to see if they can be manipulated to increase Parkin levels, thereby increasing cell survival to prevent disease."
This work was supported by a $2.7 million National Institutes of Health (NIH) grant (EY02678) to Kantorow and his collaborators from the National Eye Institute that seeks to identify those mechanisms that regulate cellular growth and differentiation.
About the Charles E. Schmidt College of Medicine:
FAU's Charles E. Schmidt College of Medicine is one of 141 accredited medical schools in the U.S. The college was launched in 2010, when the Florida Board of Governors made a landmark decision authorizing FAU to award the M.D. degree. After receiving approval from the Florida legislature and the governor, it became the 134th allopathic medical school in North America. With more than 70 full and part-time faculty and more than 1,300 affiliate faculty, the college matriculates 64 medical students each year and has been nationally recognized for its innovative curriculum. To further FAU's commitment to increase much needed medical residency positions in Palm Beach County and to ensure that the region will continue to have an adequate and well-trained physician workforce, the FAU Charles E. Schmidt College of Medicine Consortium for Graduate Medical Education (GME) was formed in fall 2011 with five leading hospitals in Palm Beach County. In June 2014, FAU's College of Medicine welcomed its inaugural class of 36 residents in its first University-sponsored residency in internal medicine.
About Florida Atlantic University:
Florida Atlantic University, established in 1961, officially opened its doors in 1964 as the fifth public university in Florida. Today, the University, with an annual economic impact of $6.3 billion, serves more than 30,000 undergraduate and graduate students at sites throughout its six-county service region in southeast Florida. FAU's world-class teaching and research faculty serves students through 10 colleges: the Dorothy F. Schmidt College of Arts and Letters, the College of Business, the College for Design and Social Inquiry, the College of Education, the College of Engineering and Computer Science, the Graduate College, the Harriet L. Wilkes Honors College, the Charles E. Schmidt College of Medicine, the Christine E. Lynn College of Nursing and the Charles E. Schmidt College of Science. FAU is ranked as a High Research Activity institution by the Carnegie Foundation for the Advancement of Teaching. The University is placing special focus on the rapid development of critical areas that form the basis of its strategic plan: Healthy aging, biotech, coastal and marine issues, neuroscience, regenerative medicine, informatics, lifespan and the environment. These areas provide opportunities for faculty and students to build upon FAU's existing strengths in research and scholarship. For more information, visit http://www.fau.edu.